Lupus Nephritis: all 338 studies
Page 1 of 4. Open to participants first (131), then studies with results posted, then the rest; newest registration first within each.
- A Study of BMS-986553 in Participants With Refractory Autoimmune DiseasesNot yet recruitingNCT07873931Phase 1
- Diastolic Dysfunction and Inflammatory Biomarkers in Lupus NephritisNot yet recruitingNCT07837544
- Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus ErythematosusNot yet recruitingNCT07805863
- Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus NephritisRecruitingNCT07799116Phase 1/2
- Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients With Lupus Nephritis: The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and C Reactive Protein to Serum Albumin RatioNot yet recruitingNCT07783711
- Lupus Nephritis Care PathwayRecruitingNCT07783152Not applicable
- SII and SIRI as Prognostic Biomarkers in Lupus NephritisNot yet recruitingNCT07780045
- A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)Not yet recruitingNCT07767188Phase 3
- Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.Not yet recruitingNCT07763821
- Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and PrednisoloneRecruitingNCT07760480Phase 4
- BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune DiseaseNot yet recruitingNCT07729995Phase 1
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard TherapyNot yet recruitingNCT07729826Phase 2
- Neutrophil Extracellular Traps and Lupus NephritisNot yet recruitingNCT07721857
- Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II TrialNot yet recruitingNCT07721363Phase 2
- Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus NephritisNot yet recruitingNCT07719322
- Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)RecruitingNCT07719140Phase 4
- Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus NephritisNot yet recruitingNCT07706998Not applicable
- The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis PopulationRecruitingNCT07700940Phase 4
- Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in ChildrenNot yet recruitingNCT07675291Not applicable
- Biomarker Development for Autoimmune Disorders Involving the KidneysRecruitingNCT07666711
- CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus ErythematosusNot yet recruitingNCT07659704Phase 1/2
- PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisRecruitingNCT07611214Phase 4
- A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus NephritisRecruitingNCT07598396Phase 2
- A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune DiseasesNot yet recruitingNCT07593911Not applicable
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisRecruitingNCT07570862Phase 2
- Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune NephropathyNot yet recruitingNCT07535138Early Phase 1
- SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory LupusRecruitingNCT07523542Phase 1/2
- CHT105 for the Treatment of Refractory Lupus NephritisEnrolling by invitationNCT07517536Not applicable
- Anti-alpha-actinin Antibodies and Lupus Nephritis ActivityNot yet recruitingNCT07505576
- Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus NephritisNot yet recruitingNCT07493655Not applicable
- A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)RecruitingNCT07491900Phase 1
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101RecruitingNCT07403188
- A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus NephritisNot yet recruitingNCT07393451Phase 2
- Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus ErythematosusNot yet recruitingNCT07364396Phase 1/2
- Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNRecruitingNCT07363460Phase 2
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentRecruitingNCT07340463Phase 2
- A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus NephritisRecruitingNCT07328581Phase 2
- Dapagliflozin in Active Lupus NephritisRecruitingNCT07323524Phase 4
- An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07236762Phase 1
- Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy TrialRecruitingNCT07225387Phase 4
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentRecruitingNCT07201129Phase 3
- The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus NephritisNot yet recruitingNCT07130448
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesRecruitingNCT07123519Phase 1
- A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRecruitingNCT07115745Phase 1
- UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus NephritisRecruitingNCT07109986Phase 1
- Safety and Efficacy of ONT01 in LupusRecruitingNCT07107659Early Phase 1
- A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingNCT07104721Phase 1
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseRecruitingNCT07085104Phase 1
- LUPKYNIS Drug-use Results SurveyRecruitingNCT07053891
- Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)RecruitingNCT07053800Phase 2
- A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesEnrolling by invitationNCT07038447Phase 1
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active GlomerulonephritisRecruitingNCT07038382Phase 2
- SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated VasculitisNot yet recruitingNCT07035834Phase 4
- Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis PatientsRecruitingNCT07017868
- MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.Not yet recruitingNCT07000292Phase 1/2
- Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisRecruitingNCT06975787Phase 1
- Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.RecruitingNCT06947473Phase 1/2
- CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAHRecruitingNCT06947460Phase 1/2
- Research Accelerated by You Lupus RegistryRecruitingNCT06927219
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseRecruitingNCT06925542Phase 1
- Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in ChildrenRecruitingNCT06904729Phase 3
- Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06902844Not applicable
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruitingNCT06897930Phase 1/2
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingNCT06839976Phase 1/2
- Predictors of Bone Mineral Density in Lupus Nephritis ActivityNot yet recruitingNCT06837558
- CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus NephritisRecruitingNCT06785519Early Phase 1
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)RecruitingNCT06711887Phase 3
- US Zamto-cel Autoimmune DiseasesRecruitingNCT06708845Phase 1
- High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)RecruitingNCT06682507
- Universal CAR-T Cell Therapy for Refractory Lupus NephritisNot yet recruitingNCT06681337Early Phase 1
- NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisRecruitingNCT06676631Phase 1
- Urinary Congophilia As an Indicator of Activity of Lupus NephritisNot yet recruitingNCT06654024
- Monitoring Lupus Nephritis Through Urinary Extracellular VesiclesRecruitingNCT06642402
- Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis PatientsRecruitingNCT06631404
- Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) PatientsNot yet recruitingNCT06610422
- Renal Survival in Patients with Lupus NephritisNot yet recruitingNCT06588192
- Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus ErythematosusRecruitingNCT06585514Phase 1/2
- The Relation Between Serum Zinc and Lupus NephritisNot yet recruitingNCT06564181
- A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)RecruitingNCT06557265Phase 1/2
- Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LNRecruitingNCT06527872
- Urinary G3BP as a Novel Biomarker in Lupus NephritisNot yet recruitingNCT06520670
- A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus ErythematosusEnrolling by invitationNCT06518668Phase 1
- Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingNCT06497387Early Phase 1
- Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingNCT06497361Early Phase 1
- A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy HospitalRecruitingNCT06491602
- Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus NephritisNot yet recruitingNCT06485648Early Phase 1
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingNCT06434363Phase 1/2
- T Regulatory Cells IN LUPUS NEPHRITISNot yet recruitingNCT06428539
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GRecruitingNCT06419205Phase 2
- A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus NephritisRecruitingNCT06406205Phase 3
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune DiseaseEnrolling by invitationNCT06375993Phase 1
- Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06350110Phase 1/2
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseRecruitingNCT06308978Phase 1
- Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN)Not yet recruitingNCT06288308
- The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney DiseasesRecruitingNCT06285279Phase 1
- Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T CellsRecruitingNCT06277427Not applicable
- Gut Microbiota Dysbiosis in Lupus NephritisNot yet recruitingNCT06231303
- Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.Not yet recruitingNCT06228222
- Wellness & Workforce Solution for Lupus/Lupus NephritisRecruitingNCT06217107Not applicable
- Disease and Biomarker Profiling of Chinese Lupus NephritisNot yet recruitingNCT06210464